Seers Inc received a bumper listing valuing it at $3.3 billion for a revenue of less than $1 million.
It is claimed that company has a breakthrough for studying proteins and for diagnostics.
Seers Inc received a bumper listing valuing it at $3.3 billion for revenue of less than $1 million. It is claimed that the company has a breakthrough for studying proteins and for diagnostics.
Let's break it down.
The product has the following elements in it:
1) It claims to create a 'Proteograph' of proteins.
It is done by breaking down protein into peptides.
The above process is widely used in research and protein studies. This is not a new thing, nor propitiatory.
2) Peptides are run through a Mass-spectrometer (mass-spec).
Mass-specs are widely used, and so far, the company is not into making it. They rely on users for the mass-spec.
3) Deep profiling the data with proteigraph.
Proteigraph-based deep proteomic profiling is an oversold concept of deep-profiling, ML-enabled data analysis, AI-based prediction.
Though the software suite is new, it is not unique. Researchers in the field analyze the data by writing python/R scripts for deep data analysis, and there are plenty of free codes available in the research journal to use. Though not a breakthrough, the software package is new.
The risk is mass-spec manufacturers have packages for several applications and data analysis. This can be easily developed by the manufacturers and independent package sellers.
4) Use of nano-particle for 'Protein-Corona'
Prof. Omid (Co-founder) and Prof. Langer (Co-founder), published their findings on 'protein-corona' between 2015-17. The latest scientific publication came out this summer, elaborating the concept and demonstrating the use of all the four components of the product.
'Protein-corona' is created by smartly using nano-particles (no-proprietary) to capture proteins with different charges.
The company reported a revenue of less than $1 million in the last two yrs of operation. Despite claiming to have research use, co-founders associated with the Harvard-MIT eco-system, and connections in the bay-area research community could not manage a revenue of more than $1 million! Does this breakthrough deserve a $3.3 billion listing valuation??
This is an elaborate marketing show pulled-off by the co-founders and gullible investors buying into it.
Avoid junk. Happy investing.
It is claimed that company has a breakthrough for studying proteins and for diagnostics.
Seers Inc received a bumper listing valuing it at $3.3 billion for revenue of less than $1 million. It is claimed that the company has a breakthrough for studying proteins and for diagnostics.
Let's break it down.
The product has the following elements in it:
1) It claims to create a 'Proteograph' of proteins.
It is done by breaking down protein into peptides.
The above process is widely used in research and protein studies. This is not a new thing, nor propitiatory.
2) Peptides are run through a Mass-spectrometer (mass-spec).
Mass-specs are widely used, and so far, the company is not into making it. They rely on users for the mass-spec.
3) Deep profiling the data with proteigraph.
Proteigraph-based deep proteomic profiling is an oversold concept of deep-profiling, ML-enabled data analysis, AI-based prediction.
Though the software suite is new, it is not unique. Researchers in the field analyze the data by writing python/R scripts for deep data analysis, and there are plenty of free codes available in the research journal to use. Though not a breakthrough, the software package is new.
The risk is mass-spec manufacturers have packages for several applications and data analysis. This can be easily developed by the manufacturers and independent package sellers.
4) Use of nano-particle for 'Protein-Corona'
Prof. Omid (Co-founder) and Prof. Langer (Co-founder), published their findings on 'protein-corona' between 2015-17. The latest scientific publication came out this summer, elaborating the concept and demonstrating the use of all the four components of the product.
'Protein-corona' is created by smartly using nano-particles (no-proprietary) to capture proteins with different charges.
The company reported a revenue of less than $1 million in the last two yrs of operation. Despite claiming to have research use, co-founders associated with the Harvard-MIT eco-system, and connections in the bay-area research community could not manage a revenue of more than $1 million! Does this breakthrough deserve a $3.3 billion listing valuation??
This is an elaborate marketing show pulled-off by the co-founders and gullible investors buying into it.
Avoid junk. Happy investing.